Press "Enter" to skip to content

AstraZeneca’s Imfinzi extends survival in first-line lung cancer – Seeking Alpha

admin 0

AstraZeneca’s Imfinzi extends survival in first-line lung cancer  Seeking Alpha

Results from a Phase 3 clinical trial, CASPIAN, evaluating AstraZeneca’s (AZN) Imfinzi (durvalumab), combined with platinum-based chemo compared to chemo …

“lung cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *